What Eli Lilly and Novo Nordisk’s earnings reveal about the future of GLP-1 sales
It was an exciting, if sometimes uncertain, year for the GLP-1 business. Just take a look at the past week. On Wednesday, Novo Nordisk (NVO) missed Wall Street estimates for…